PMID- 22615013
OWN - NLM
STAT- MEDLINE
DCOM- 20121106
LR  - 20211021
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 57
IP  - 9
DP  - 2012 Sep
TI  - Proton pump inhibitors increase the incidence of bone fractures in hepatitis C 
      patients.
PG  - 2416-22
LID - 10.1007/s10620-012-2185-5 [doi]
AB  - BACKGROUND: While proton pump inhibitors (PPI) may increase the risk of bone 
      fractures, the incidence of new bone fractures in a chronic hepatitis C virus 
      (HCV) infected cohort, with or without PPI exposure, has not been explored. 
      METHODS: A retrospective cohort study of the incidence of bone fractures over 10 
      years in 9,437 HCV antibody positive patients in the Dallas VA Hepatitis C 
      Registry was performed. The study endpoint was the incidence of verified new bone 
      fractures per patient-years (pt-yrs) in PPI users compared to non-PPI users. PPI 
      use was defined as those taking a PPI for >/=360 days. Pt-yrs of exposure for PPI 
      users began on the first PPI prescription date, and pt-yrs of exposure for 
      non-PPI users began with first date of any non-PPI prescription. For both HCV 
      groups, the final date of patients' study duration was defined by end of PPI 
      exposure, bone fracture occurrence, death or end of study evaluation period. 
      Exclusion criteria included use of bone health modifying medications >/=30 days. 
      Statistical differences in fracture incidence between groups were determined by 
      multivariate regression analysis. RESULTS: Among the total study population 
      analyzed (n = 2,573), 109 bone fractures occurred. Unadjusted bone fracture 
      incidences were 13.99/1,000 pt-yrs vs. 5.86/1,000 pt-yrs in PPI and non-PPI 
      users, respectively. The adjusted hazard ratio for new bone fractures was 3.87 
      (95 % CI 2.46-6.08) (p < 0.001) in PPI users. CONCLUSIONS: In patients with 
      chronic HCV, use of PPI for >1 year increased the risk of new bone fractures by 
      more than threefold.
FAU - Mello, Michael
AU  - Mello M
AD  - Department of Medical Service, Division of Digestive Diseases, University of 
      Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. 
      Michael.mello@phhs.org
FAU - Weideman, Rick A
AU  - Weideman RA
FAU - Little, Bertis B
AU  - Little BB
FAU - Weideman, Mark W
AU  - Weideman MW
FAU - Cryer, Byron
AU  - Cryer B
FAU - Brown, Geri R
AU  - Brown GR
LA  - eng
PT  - Journal Article
DEP - 20120522
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Hepatitis C Antibodies)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Fractures, Bone/*chemically induced/epidemiology
MH  - Hepatitis C Antibodies/blood
MH  - Hepatitis C, Chronic/*complications/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Texas/epidemiology
EDAT- 2012/05/23 06:00
MHDA- 2012/11/07 06:00
CRDT- 2012/05/23 06:00
PHST- 2011/10/10 00:00 [received]
PHST- 2012/04/12 00:00 [accepted]
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/11/07 06:00 [medline]
AID - 10.1007/s10620-012-2185-5 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2012 Sep;57(9):2416-22. doi: 10.1007/s10620-012-2185-5. Epub 2012 
      May 22.